Galderma and Taro Pharmaceutical Industries Ltd. (Taro) announced they have signed a definitive agreement for Taro to acquire Alchemee, formerly The Proactiv Company (TPC}, from Galderma. The agreement between Galderma and Taro includes Alchemee’s business and assets around the world, including the Proactiv brand.
“We are excited to add Proactiv to Taro’s broad portfolio of prescription and over-thecounter dermatology products. We look forward to welcoming the Alchemee team into Taro and working together to continue to make a difference to the millions of people living with acne around the world,” said Uday Baldota, Chief Executive Officer, Taro.
Commenting on the development, Flemming Ornskov, CEO, Galderma, said, “we are proud of the work we have done together to serve customers suffering from acne around the world through Proactiv®. I am confident that Taro is the right owner to build on Alchemee’s strong foundation. Their vision is aligned to Alchemee which comes with an incredible legacy and brand equity, and a great team with a clear plan for future success.”
The acquisition is subject to customary closing conditions and any necessary regulatory approvals. Financial terms of the transaction have not been disclosed.
HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.